4BB.L
Price:
$1125
Market Cap:
$174.06M
4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.
Industry
Biotechnology
IPO Date
2021-02-17
Stock Exchange
LSE
Ticker
4BB.L
According to 4basebio PLC’s latest financial reports and current stock price. The company's current PE Ratio is -14.42. This represents a change of 115.93% compared to the average of -6.68 of the last 4 quarters.
The mean historical PE Ratio of 4basebio PLC over the last ten years is -41.48. The current -14.42 PE Ratio has changed 3.38% with respect to the historical average. Over the past ten years (40 quarters), 4BB.L's PE Ratio was at its highest in in the June 2023 quarter at -4.98. The PE Ratio was at its lowest in in the June 2019 quarter at -49.14.
Average
-41.48
Median
-23.42
Minimum
-98.28
Maximum
-10.93
Discovering the peaks and valleys of 4basebio PLC PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -10.93
Minimum Annual Increase = -59.50%
Minimum Annual PE Ratio = -98.28
Year | PE Ratio | Change |
---|---|---|
2023 | -10.93 | -35.64% |
2022 | -16.98 | -27.48% |
2021 | -23.42 | -59.50% |
2020 | -57.82 | -41.17% |
The current PE Ratio of 4basebio PLC (4BB.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-17.11
5-year avg
-41.48
10-year avg
-41.48
4basebio PLC’s PE Ratio is less than Abingdon Health Plc (-8.57), less than Arecor Therapeutics plc (-1.53), less than Verici Dx plc (-0.78), less than Oncimmune Holdings plc (-0.23), less than AMTE Power plc (0),
Company | PE Ratio | Market cap |
---|---|---|
-8.57 | $12.10M | |
-1.53 | $15.67M | |
-0.78 | $2.75M | |
-0.23 | $1.27M | |
0 | $2.15M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 4basebio PLC using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like 4basebio PLC or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is 4basebio PLC's PE Ratio?
How is the PE Ratio calculated for 4basebio PLC (4BB.L)?
What is the highest PE Ratio for 4basebio PLC (4BB.L)?
What is the 3-year average PE Ratio for 4basebio PLC (4BB.L)?
What is the 5-year average PE Ratio for 4basebio PLC (4BB.L)?
How does the current PE Ratio for 4basebio PLC (4BB.L) compare to its historical average?